SEARCH · Search NASA
Results for “PROLINE”
Search indexed NASA NTRS and DOE OSTI research on propulsion, heat transfer, battery materials and energy systems. Follow report and document links to the original sources.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Influence of Hofmeister Ions on the Structure of Proline-Based Peptide Models: A Combined Experimental and Molecular Modeling Study
Not Available
Photoinduced Covalent Irreversible Inactivation of Proline Dehydrogenase by S-Heterocycles
Explore the source record for details and available documents.
Covalent Modification of the Flavin in Proline Dehydrogenase by Thiazolidine-2-Carboxylate
Abstract not provided
Structure-Based Discovery of Proline-Derived Arginase Inhibitors with Improved Oral Bioavailability
Explore the source record for details and available documents.
Comprehensive Strategies to Bicyclic Prolines: Applications in the Synthesis of Potent Arginase Inhi
Explore the source record for details and available documents.
A Unique cis-3-Hydroxy-l-proline Dehydratase in the Enolase Superfamily
Abstract not provided
Novel Potent Hepatitis C Virus NS3 Serine Protease Inhibitors Derived from Proline-Based Macrocycles
Abstract not provided
The mechanism of inhibition of protein synthesis by the proline-rich peptide oncocin
Abstract not provided
Proline-based tripodal cages with guest-adaptive features for capturing hydrophilic and amphiphilic fluoride substances
Not Available
Structural and energetic basis of ALS-causing mutations in the atypical proline-tyrosine nuclear localization signal of the Fused in Sarcoma protein (FUS)
Mutations in the proline/tyrosine–nuclear localization signal (PY-NLS) of the Fused in Sarcoma protein (FUS) cause amyotrophic lateral sclerosis (ALS). Here we report the crystal structure of the FUS PY-NLS bound to its nuclear import receptor Karyopherinβ2 (Kapβ2; also known as Transportin). The FUS PY-NLS occupies the structurally invariant C-terminal arch of Kapβ2, tracing a path similar to that of other characterized PY-NLSs. Unlike other PY-NLSs, which generally bind Kapβ2 in fully extended conformations, the FUS peptide is atypical as its central portion forms a 2.5-turn α-helix. The Kapβ2-binding epitopes of the FUS PY-NLS consist of an N-terminal PGKM hydrophobic motif, a central arginine-rich α-helix, and a C-terminal PY motif. ALS mutations are found almost exclusively within these epitopes. Each ALS mutation site makes multiple contacts with Kapβ2 and mutations of these residues decrease binding affinities for Kapβ2 (K D for wild-type FUS PY-NLS is 9.5 nM) up to ninefold. Thermodynamic analyses of ALS mutations in the FUS PY-NLS show that the weakening of FUS-Kapβ2 binding affinity, the degree of cytoplasmic mislocalization, and ALS disease severity are correlated.
Three crystal forms of the bifunctional enzyme proline utilization A (PutA) from Bradyrhizobium japonicum
Abstract not provided
Structures of Human DPP7 Reveal the Molecular Basis of Specific Inhibition and the Architectural Diversity of Proline-Specific Peptidases
Abstract not provided
Proline-Rich Polypeptide 1 and G X -NH 2 : Molecular and Genetic Mechanisms of Hematopoiesis Regulation
LifeTime™ is a clinical-stage pharmaceutical company focused on that focuses on "fast tracked" small molecules designed to treat and prevent the recurrence of life-threatening chronic infectious and malignant diseases. It is a company focused on the clinical development and commercialization of promising new compounds for human therapeutics. Its lead compound is Beta LT™, an anti-cancer immune stimulant, which is currently in Phase I/II trials in Canada and waiting for Phase I/II start-up in America. While current approaches generally cause remissions, the few cells (or viruses) not killed by current therapy generally multiply, ultimately killing the person. To prevent this, they specialize in developing novel, to date completely non-toxic, long-term therapeutic products.
Native proline-rich motifs exploit sequence context to target actin-remodeling Ena/VASP protein ENA
Explore the source record for details and available documents.
Use of prolines for improving growth and/or yield
The present invention describes a composition including a mixture of L- and D-pyroglutamate stereoisomers in a ratio of L to D of from about 80:20 to about 97:3, and, a carrier medium for application of the L- and D-pyroglutamate stereoisomers to a target plant. The composition can also be used as a germination medium and may be incorporated into a seed coat for assisting in germination. The present invention further describes a method of increasing the agronomic performance of a target plant by treating a target plant with a composition including a mixture of L- and D-pyroglutamate stereoisomers in a ratio of L to D of from about 80:20 to about 97:3 and a carrier medium for said L- and D-pyroglutamate stereoisomers.
Use of prolines for improving growth and/or yield
The present invention describes a composition including a mixture of L- and D-pyroglutamate stereoisomers in a ratio of L to D of from about 80:20 to about 97:3 , and, a carrier medium for application of the L- and D-pyroglutamate stereoisomers to a target plant. The composition can also be used as a germination medium and may be incorporated into a seed coat for assisting in germination. The present invention further describes a method of increasing the agronomic performance of a target plant by treating a target plant with a composition including a mixture of L- and D-pyroglutamate stereoisomers in a ratio of L to D of from about 80:20 to about 97:3 and a carrier medium for said L- and D-pyroglutamate stereoisomers.